(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 10.7MM | +39% |
Operating Income | -21.4MM | - |
Operating Expenses | 32.1MM | -38% |
Net Income | -19.5MM | -53% |
R&D | 21.5MM | -30% |
G&A | 10.1MM | -21% |
Interest Expense | 1MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all […]
Key Insights Mersana Therapeutics' estimated fair value is US$6.60 based on 2 Stage Free Cash Flow to Equity Mersana...
Mersana Therapeutics ( NASDAQ:MRSN ) Full Year 2023 Results Key Financial Results Revenue: US$36.9m (up 39% from FY...
Q4 2023 Mersana Therapeutics Inc Earnings Call
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of 20% and 62.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Advancements in Clinical Trials and Strategic Collaborations Highlighted
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) --
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference Format:Panel discussionDate/Time:Tuesday, March 5, 2024, at 9:10 a.m. Easte
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call an